Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Am J Hematol. 2023 Dec;98(12):E369-E372. doi: 10.1002/ajh.27101. Epub 2023 Sep 23.
We used the information component (IC), a disproportionate Bayesian analysis comparing the number of observed versus expected adverse drug reactions, to determine the potential association between anti-neoplastic agents and thrombotic microangiopathy (TMA). The IC indicates the lower end of 95% of IC, in which a value >0 suggests a disproportionality signal between the drug of interest and the adverse drug reaction. Carfilzomib had the highest IC for TMA among all studied chemotherapies followed by gemcitabine, mitomycin, bevacizumab, and bortezomib.
我们使用信息成分（IC），一种不成比例的贝叶斯分析，比较观察到的不良反应数量与预期数量，以确定抗肿瘤药物与血栓性微血管病（TMA）之间的潜在关联。IC 表示 95%IC 的下限，其中值>0表示感兴趣的药物与不良反应之间存在不成比例的信号。在所有研究的化疗药物中，卡非佐米对 TMA 的 IC 最高，其次是吉西他滨、丝裂霉素、贝伐珠单抗和硼替佐米。
